PCV12- ACHIEVEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY LDL-C TARGET BY HYPERCHOLESTEROLAEMIC PATIENTS RECEIVING ROSUVASTATIN COMPARED TO ATORVASTATIN, PRAVASTATIN OR SIMVASTATIN- AN EVIDENCE-BASED MEDICINE APPROACH
May 1, 2003, 00:00
10.1016/S1098-3015(10)64127-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)64127-7/fulltext
Title :
PCV12- ACHIEVEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY LDL-C TARGET BY HYPERCHOLESTEROLAEMIC PATIENTS RECEIVING ROSUVASTATIN COMPARED TO ATORVASTATIN, PRAVASTATIN OR SIMVASTATIN- AN EVIDENCE-BASED MEDICINE APPROACH
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64127-7&doi=10.1016/S1098-3015(10)64127-7
First page :
Section Title :
Open access? :
No
Section Order :
327